GlassScriptPhysician profile
Keith A Picou
NPI 1881699270
$7,810.98
in general payments reported to CMS, 2019-2025
30 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $823 · 2021: $1,080 · 2022: $1,507 · 2023: $1,354 · 2024: $1,657 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.45 |
| Education | $247.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,402.56 | 2019-2025 | Tremfya |
| Abbvie INC. | $894.36 | 2019-2024 | |
| Genzyme Corporation | $805.39 | 2020-2024 | |
| Amgen INC. | $779.47 | 2019-2025 | Otezla, Otezla |
| Glaxosmithkline, LLC. | $525.37 | 2021-2025 | Nucala |
| Novartis Pharmaceuticals Corporation | $506.11 | 2019-2024 | |
| Stryker Corporation | $462.69 | 2019-2022 | |
| Dermavant Sciences, INC. | $306.47 | 2023-2024 | Vtama |
| Pfizer INC. | $250.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $248.39 | 2022-2024 | Sotyktu |
| Optinose US, INC. | $229.42 | 2020-2023 | |
| Lilly USA, LLC | $227.90 | 2019-2023 | Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $185.57 | 2019-2023 | Absorica Ld, Winlevi |
| Ucb, INC. | $164.10 | 2023-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $117.00 | 2019-2025 | Nemluvio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $113.72 | 2019-2024 | Adbry |
| Strata Skin Sciences, INC. | $87.08 | 2019-2022 | |
| Phadia US INC. | $82.26 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $74.19 | 2022-2023 | Nuzyra |
| Medtronic USA, INC. | $60.94 | 2019-2020 | |
| Medtronic, INC. | $57.59 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.40 | 2020-2024 | Duobrii, Siliq |
| Regeneron Healthcare Solutions, INC. | $38.61 | 2022-2024 | Libtayo |
| Melinta Therapeutics, LLC | $34.52 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.61 | 2024 | Spevigo |
| Genentech USA, INC. | $27.57 | 2021 | |
| Janssen Scientific Affairs, LLC | $24.00 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $17.66 | 2023 | |
| Nabriva Therapeutics, Plc | $12.06 | 2022 | |
| Organon LLC | $6.25 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Picou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.